//
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial
The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5)
Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association
Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction"
Dapagliflozin for treating chronic heart failure with reduced ejection fraction
Association of Reduced Apical Untwisting With Incident HF in Asymptomatic Patients With HF Risk Factors
Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure
Ejection Fraction Pros and Cons: JACC State-of-the-Art Review